Clinical Trials Directory

Trials / Unknown

UnknownNCT05580172

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
6 (estimated)
Sponsor
ReHeva Biosciences,Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

Detailed description

This is a Phase 1 open label dose ranging study to assess the safety and tolerability of oral RH324 in advanced non-small cell lung cancer

Conditions

Interventions

TypeNameDescription
DRUGRH324polymolecular

Timeline

Start date
2022-06-01
Primary completion
2024-06-01
Completion
2025-01-01
First posted
2022-10-14
Last updated
2022-10-17

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05580172. Inclusion in this directory is not an endorsement.

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer (NCT05580172) · Clinical Trials Directory